who medicines strategy - libdoc.who.int - World Health Organization

More documents

Recommendations

Info

WHO MEDICINES STRATEGY 2004-2007 | 58EO 3.1Access to essential medicinesimproved, including medicines forHIV/AIDS, malaria, TB, childhoodillnesses, and noncommunicablediseasesRationaleIn 2001, the Commission on Macroeconomicsand Health 22 demonstrated the close linksbetween health and poverty reduction. The lackof access to essential medicines and other healthinterventions to prevent or treat diseases suchas HIV/AIDS, TB, and malaria results in highmortality and morbidity and holds back socialand economic development. In addition, in somecountries, the lack of medicines in health facilitieshas lowered people’s confidence in the healthcare delivery system. As a result, other servicesoffered by the health system, including vitalimmunization programmes, have been adverselyaffected.ProgressThe Stop TB Partnership and the Global DrugFacility have demonstrated that: new resourcescan be mobilized; innovative partnerships, evenat grass-roots level, can be forged for effectivecountry level action; and pooled resources cancreate an effective negotiating tool for pricesetting in non-structured markets. In addition,through joint product development agreements,WHO has been able to achieve differential pricesfor a number of key antimalarial drug products.Standard treatment guidelines for HIV/AIDS andmalaria have been reviewed and updated andreflected in the WHO Model List of EssentialMedicines and Formulary. These guidelines helpcountries to select drug products that are optimalfor their setting, taking into account both theepidemiological situation and drug resistancepatterns. WHO is also contributing to ensuring thequality of new medicines for HIV/AIDS, TB, andmalaria through the prequalification process. Inthis way, national medicine supply systems andregulatory authorities are able to make evidencebaseddecisions about medicines.Price information on selected essential medicinesis provided through a collaborative effortinvolving WHO and partners — allowing nationalprogrammes to compare medicine prices offeredby various sources. This is a valuable tool forensuring competitive pricing in the internationalmedicines market.ChallengesThe high disease burden due to HIV/AIDS,TB, and malaria in many countries is a majorchallenge for governments. Efforts to improveaccess to essential medicines for these threediseases require a substantial increase in bothhuman and financial resources, as well asstrengthened medicines supply systems. Thehigh cost of individual treatment, especially forlifelong treatment for HIV/AIDS, is a major hurdlefor many governments and individuals. Effectivedelivery of many of the medicines for thesediseases requires accurate diagnosis and closemonitoring of the patient’s response to treatment.To achieve this, it is vital that health systemsdevelop and implement the necessary supportinginfrastructure, train health staff, and providethe information needed by patients to ensureoptimal therapy. The development of resistance tocurrently available therapies is a significant threatto treatment. Innovative measures to containthe rate and extent of drug resistance need to beidentified.
COMPONENTS OF THE STRATEGY | 59Figure 14:Number of people on ARV treatment by region, 2002-20051000800600ABCDEFGHSouthern AfricaEastern AfricaWest & Central AfricaIndiaOther Asia & PacificLatin America & CaribbeanEastern Europe &Central AsiaNorth Africa | Near East4002000A B C D E F G HSource: WHO2005200420032002Meeting the challenges 2004-2007Over the next four years WHO will:> support global and sub-regional initiativesto expand access to essential medicines byadopting a more focused approach througha reorientation of the efforts of all WHOdepartments, including EDM, around thechallenges of the three diseases.> provide: the relevant standards (normativework); guidance (e.g. through the prequalificationof suppliers); information (e.g.on prices, patents, and regulatory status);essential medicines programme managementexperience and staffing; and country support.> develop and put into operation the WHOAIDS Drugs and Diagnostics Facility and theMalaria Facility. The effective functioningof these facilities will depend on the abilityof EDM to build on internal and externalpartnerships and to provide intensifiedtechnical guidance and operational support.OUTCOME INDICATORS1999 2003 2007No. of countries where less than 50% of the populationhas access to essential medicines#REPORTING % TARGET#REPORTING % TARGET29/184 16% 14% 15/103 15% 14%
Page 10 and 11:
WHO MEDICINES STRATEGY 2004-2007 |x
Page 12 and 13:
WHO MEDICINES STRATEGY 2004-2007 |x
Page 14 and 15:
WHO MEDICINES STRATEGY 2004-2007 |
Page 23: MEDICINESAND PUBLIC HEALTH
Page 26 and 27: WHO MEDICINES STRATEGY 2004-2007 |
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 157 and 158:
REFERENCES
Page 159 and 160:
REFERENCES | 1471Annual report 2000
Page 161 and 162:
REFERENCES | 14912 th Model List of
show all

who medicines strategy - libdoc.who.int - World Health Organization

Create successful ePaper yourself

Delete template?

Save as template?